Allergan’s Juvederm gets multi-center trial
This article was originally published in The Gray Sheet
Executive Summary
Allergan's hyaluronic acid dermal filler products Juvederm Ultra and Juvederm Ultra Plus commence a multi-center, open-label trial designed to gain information on physicians' use of the products. FDA approved the Juvederm fillers in June, and the firm plans a January 2007 national launch. The fillers join Allergan's Botox botulinum toxin type A in its portfolio of physician-dispensed facial aesthetics. Allergan acquired the products in March as part of its acquisition of Inamed (1"The Gray Sheet" June 12, 2006, p. 15)...
You may also be interested in...
Mentor Injects Dermal Filler Pipeline With Genzyme R&D
Mentor will market future Genzyme-developed hyaluronic acid dermal filler products to complement its existing Puragen hyaluronic acid device platform under a partnership agreement announced Oct. 30
Allergan’s Juvederm Dermal Filler Approved, But Market Will Wait
Although Allergan's Juvederm dermal filler was approved by FDA ahead of schedule, the firm does not plan to market the cosmetic device immediately
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.